Healthcare solutions provider GE HealthCare Technologies Inc (NASDAQ: GEHC) and non-profit organisation Mayo Clinic announced on Wednesday the launch of the MI-BET (Molecular Imaging Biomarker-Based End of Therapy Trial) research collaboration to evaluate a more personalised approach to radioligand therapy for patients with advanced prostate cancer.

The study will assess whether imaging, clinical outcomes and blood-based biomarkers can support individualised treatment decisions, including adapting therapy based on a patient's response rather than using a fixed number of treatment cycles.

MI-BET will use GE HealthCare's StarGuide SPECT/CT imaging technology and MIM Software's MIM LesionID Pro to monitor tumour response throughout treatment. The research also aims to identify predictive markers that could help clinicians anticipate treatment responses and guide therapy earlier.

The study will be conducted at Mayo Clinic's Rochester, Minnesota campus and stems from the organisations' 2023 Strategic Radiology Research Alliance. Mayo Clinic will also become the first US site to evaluate GE HealthCare's next-generation StarGuide GX SPECT/CT technology, including its potential to reduce scan times and improve tumour assessment precision.